Premium
Bone Affinity of a Bisphosphonate‐Conjugated Protein in Vivo
Author(s) -
Uludag Hasan,
Gao Tiejun,
Wohl Gregory R.,
Kantoci Darko,
Zernicke Ronald F.
Publication year - 2000
Publication title -
biotechnology progress
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 129
eISSN - 1520-6033
pISSN - 8756-7938
DOI - 10.1021/bp000066y
Subject(s) - medullary cavity , ovariectomized rat , chemistry , in vivo , bovine serum albumin , bisphosphonate , tibia , medicine , bone tissue , endocrinology , osteoporosis , biochemistry , anatomy , biology , microbiology and biotechnology , hormone
Growth factors capable of stimulating bone formation are potential therapeutic agents for osteoporosis treatment. It is essential, however, that a targeting mechanism is incorporated into the growth factors to deposit them at osseous tissue with minimal distribution to extraskeletal sites. To this end, a strategy has been developed in which a bone‐seeking molecule, 1‐amino‐1,1‐diphosphonate methane (aminoBP), was chemically conjugated to a model protein, bovine serum albumin (BSA). This study was carried out to assess the bone affinity of the conjugates in a tibia injection model. Using ovariectomized (OVX) rats, initial (3 h) retention of BSA and aminoBP‐BSA were found to be equivalent when injected into the medullary cavity of tibia. After 1 day, an 8‐ and 12‐fold higher tibiae retention of the protein was obtained in normal and OVX rats as a result of aminoBP conjugation. A similar result (∼12‐fold difference) was also obtained in OVX rats after 3 days. We concluded that aminoBP conjugation to BSA imparted a high bone affinity and enhanced bone retention of proteins in normal and OVX rats.